New ANDA Cases

Fall 2018

GENERICally Speaking: A Hatch Waxman Litigation Bulletin
Case Name Date Filed Judge Drug Patent No(s).
Teijin Ltd. v. Torrent Pharms. Ltd., 18-0987 (D. Del.) 2-Jul-18 Vacant Judgeship (2017) Uloric® (febuxostat tablets) 7,361,676,
8,372,872,
9,107,912
Dr. Reddy’s Labs. Inc. v. Pozen Inc., IPR2018-01341 (PTAB) 2-Jul-18 N/A Vimovo® (esomeprazole magnesium / naproxen delayed-release tablets) 9,393,208
Boehringer Ingelheim Pharms., Inc. v. Apotex Inc., 18-11350 (D.N.J.) 3-Jul-18 Hon. Michael A. Shipp Gilotrif® (afatinib tablets) 8,426,586
Celgene Corp. v. Amneal Pharms. LLC, 18-11358 (D.N.J.) 3-Jul-18 Hon. Michael A. Shipp Otezla® (apremilast tablets) 6,962,940,
7,427,638,
7,659,302,
7,893,101,
8,455,536, 
9,018,243
Celgene Corp. v. Aurobindo Pharma Ltd., 18-1005 (D. Del.) 6-Jul-18 Hon. Richard G. Andrews Otezla® (apremilast tablets) 6,962,940,
7,208,516,
7,427,638,
7,659,302,
7,893,101,
8,455,536,
8,802,717,
9,018,243,
9,872,854
Cosmo Technologies Ltd. v. Actavis Labs. FL, Inc., 18-1006 (D. Del.) 6-Jul-18 Hon. Leonard P. Stark Uceris® (budesonide extended-release tablets) 9,737,489,
9,592,203
Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01358 (PTAB) 6-Jul-18 N/A Kerydin® (tavaborole topical solution) 9,549,938
Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01359 (PTAB) 6-Jul-18 N/A Kerydin® (tavaborole topical solution) 9,566,289
Horizon Pharma, Inc. v. Alkem Labs. Ltd., 18-1014 (D. Del.) 9-Jul-18 Hon. Leonard P. Stark Duexis® (ibuprofen / famotidine tablets) 8,067,033,
8,067,451,
8,309,127,
8,318,202,
8,449,910,
8,501,228
Celgene Corp. v. Sandoz, Inc., 18-1764 (D. Col.) 10-Jul-18 Hon. William J. Martinez Otezla® (apremilast tablets) 6,962,940,
7,208,516,
7,427,638,
7,659,302,
7,893,101,
8,455,536,
8,802,717,
9,018,243,
9,872,854
Celgene Corp. v. Lotus Pharm. Co., Ltd., 18-11518 (D.N.J.) 10-Jul-18 Hon. Susan D. Wigenton Revlimid® (lenalidomide capsules) 7,977,357,
8,193,219,
8,431,598
Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01360 (PTAB) 10-Jul-18 N/A Kerydin® (tavaborole topical solution) 9,566,290
Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01361 (PTAB) 10-Jul-18 N/A Kerydin® (tavaborole topical solution) 9,572,823
Eli Lilly and Co. v. Torrent Pharms. Ltd., 18-11543 (D.N.J.) 11-Jul-18 Hon. William H. Walls Cialis® (tadalafil tablets) 6,943,166
Celgene Corp. v. Pharmascience Inc., 18-11545 (D.N.J.) 11-Jul-18 Hon. Michael A. Shipp Otezla® (apremilast tablets) 6,962,940,
7,427,638,
7,659,302,
7,893,101,
8,455,536,
9,018,243
Celgene Corp. v. Amneal Pharms. LLC, 18-1032 (D. Del.) 12-Jul-18 Hon. Richard G. Andrews Otezla® (apremilast tablets) 6,962,940,
7,427,638,
7,659,302,
7,893,101,
8,455,536,
9,018,243
H. Lundbeck A/S v. Apicore US LLC, 18-1034 (D. Del.) 12-Jul-18 Hon. Leonard P. Stark Trintellix® (vortioxetine hydrobromide tablets) 7,144,884,
8,476,279,
8,722,684,
8,969,355,
9,227,946,
9,861,630
Novartis Pharms. Corp. v. Apotex Inc., 18-1038 (D. Del.) 13-Jul-18 Hon. Leonard P. Stark Gilenya® (fingolimod capsules) 9,187,405
Novartis Pharms. Corp. v. Teva Pharms. USA, Inc., 18-1039 (D. Del.) 13-Jul-18 Hon. Leonard P. Stark Gilenya® (fingolimod capsules) 9,187,405
Novartis Pharms. Corp. v. Sun Pharm. Indus., Ltd., 18-1040 (D. Del.) 13-Jul-18 Hon. Leonard P. Stark Gilenya® (fingolimod capsules) 9,187,405
Mylan Pharms. Inc. v. Biogen MA, Inc., IPR2018-01403 (PTAB) 13-Jul-18 N/A Tecfidera® (dimethyl fumarate delayed-release capsules) 8,399,514
Takeda Pharm. Co. Ltd. v. Zydus Pharms. (USA) Inc., 18-11792 (D.N.J.) 18-Jul-18 Hon. Freda L. Wolfson Prevacid® SoluTab™ (lansoprazole delayed-release orally-disintegrating tablets) 9,901,546
Genzyme Corp. v. Gland Pharma Ltd., 18-1071 (D. Del.) 19-Jul-18 Hon. Kent A. Jordan Mozobil® (plerixafor for injection) RE42,152,
7,897,590,
6,987,102
Eagle Pharms., Inc. v. Hospira, Inc., 18-1074 (D. Del.) 19-Jul-18 Hon. Leonard P. Stark Bendeka® (bendamustine HCl for injection) 9,572,887,
10,010,533,
9,034,908,
9,144,568,
9,597,397,
9,597,398,
9,597,399,
9,000,021,
9,579,384
Perrigo Research & Development Co. v. GlaxoSmithKline Consumer Healthcare, L.P., 18-11835 (D.N.J.) 29-Jul-18 Hon. Brian R. Martinotti Nicorette® (nicotine polacrilex lozenge) 8,501,164,
8,940,772
Adare Pharms., Inc. v. Teva Pharms. Int’l GMBH, 18-1079 (D. Del.) 20-Jul-18 Hon. Mitchell S. Goldberg Amrix® (cyclobenzaprine HCl extended-release capsules) 9,399,025,
9,375,410
Mallinckrodt Hospital Products IP Ltd. v. B. Braun Medical Inc., 18-1090 (D. Del.) 24-Jul-18 Hon. Leonard P. Stark Ofirmev® (acetaminophen for injection) 9,987,238
Osi Pharms., LLC v. Shilpa Medicare Ltd., 18-1096 (D. Del.) 25-Jul-18 Hon. Gregory M. Sleet Tarceva® (erlotinib HCl tablets) 6,900,221
AstraZeneca Pharms. LP v. Accord Healthcare, Inc., 18-12051 (D.N.J.) 25-Jul-18 Hon. Renee Marie Bumb Faslodex® (fulvestrant for injection) 6,774,122,
7,456,160,
8,329,680,
8,466,139
Shire-NPS Pharms., Inc. v. Par Pharm. Cos., Inc., 18-1115 (D. Del.) 28-Jul-18 Hon. Richard G. Andrews Gattex® (teduglutide for injection) 9,968,655,
9,968,656,
9,968,658,
9,974,835,
9,974,837,
9,981,014,
9,981,016,
9,987,334
Santen Pharm. Co. Ltd., Micro Labs Ltd., 18-12333 (D.N.J.) Aug. 1, 2018 Hon. Brian R. Martinotti Zioptan® (tafluprost ophthalmic solution) 9,999,593
Eli Lilly and Co. v. Umedica Labs. Pvt., Ltd., 18-12385 (D.N.J.) Aug. 2, 2018 Hon. William H. Walls Cialis® (tadalafil tablets) 6,943,166
Neptune Generics, LLC v. Corcept Therapeutics, Inc., IPR2018-01494 (PTAB) Aug. 2, 2018 N/A Korlym® (mifepristone tablets) 8,921,348
Dr. Reddy’s Labs., Inc. v. Celgene Corp., IPR2018-01504 (PTAB) Aug. 3, 2018 N/A Revlimid® (lenalidomide capsules) 9,056,120
Dr. Reddy’s Labs., Inc. v. Celgene Corp., IPR2018-01507 (PTAB) Aug. 3, 2018 N/A Revlimid® (lenalidomide capsules) 8,404,717
Dr. Reddy’s Labs., Inc. v. Celgene Corp., IPR2018-01509 (PTAB) Aug. 3, 2018 N/A Revlimid® (lenalidomide capsules) 7,189,740
Fresenius Kabi USA, LLC v. Custopharm, Inc., 18-0665 (W.D. Tex.) Aug. 6, 2018 Hon. Lee Yeakel Naropin® (ropivacaine HCl for injection) 8,118,802,
8,162,915
Taro Pharms. U.S.A., Inc. v. Glenmark Pharms. Ltd., 18-12569 (D.N.J.) Aug. 8, 2018 Hon. John Michael Vazquez Topicort® (desoximetasone topical spray) 8,277,780,
8,715,624
Horizon Therapeutics, LLC v. Par Pharm., Inc., 18-1224 (D. Del.) Aug. 10, 2018 Hon. Richard G. Andrews Ravicti® (glycerol phenylbutyrate oral liquid) 8,642,012
Allergan, Inc. v. Saptalis Pharms., LLC, 18-1231 (D. Del.) Aug. 10, 2018 Hon. Leonard P. Stark Restasis® (cyclosporine ophthalmic emulsion) 8,633,162,
8,642,556
AstraZeneca LP v. Hisun Pharm. (Hangzhou) Co., Ltd., 18-1232 (D. Del.) Aug. 10, 2018 Hon. Richard G. Andrews Brilinta® (ticagrelor tablets) RE46,276,
7,250,419,
7,265,124
Boehringer Ingelheim Pharms., Inc. v. Lupin Atlantis Holdings SA, 18-12663 (D.N.J.) Aug. 10, 2018 Hon. Brian R. Martinotti Spiriva® HandiHaler® (tiotropium bromide inhalation powder) 7,070,800,
7,694,676
Athenex Pharma Solutions, LLC v. Par Pharm., Inc., 18-0896 (W.D.N.Y.) Aug. 13, 2018 Hon. Geoffrey Crawford Vasostrict® (vasopressin injection) 9,375,478,
9,687,526,
9,744,209,
9,744,239,
9,750,785,
9,937,223
Shionogi Inc. v. Zydus Pharms. (USA) Inc., 18-12898 (D.N.J.) Aug. 16, 2018 Hon. Brian R. Martinotti Fortamet® (metformin HCl extended-release tablets) 6,790,459,
6,866,866
Par Pharm., Inc. v. Horizon Therapeutics, LLC, IPR2018-01550 (PTAB) Aug. 21, 2018 N/A Ravicti® (glycerol phenylbutyrate oral liquid) 9,561,197
Valeant Pharms. Int’l v. Actavis Labs. FL., Inc., 18-1288 (D. Del.) Aug. 22, 2018 Hon. Leonard P. Stark Uceris® (budesonide extended-release tablets) 10,052,286
Biofrontera Inc. v. Dusa Pharms., Inc., IPR2018-01585 (PTAB) Aug. 22, 2018 N/A Levulan® (aminolevulinic acid HCl topical solution) 8,216,289
Biofrontera Inc. v. Dusa Pharms., Inc., IPR2018-01585 (PTAB) Aug. 22, 2018 N/A Levulan® (aminolevulinic acid HCl topical solution) 9,723,991
Insys Therapeutics, Inc. v. Teva Pharms. USA, Inc., 18-1308 (D. Del.) Aug. 23, 2018 Hon. Colm F. Connolly Subsys® (fentanyl sublingual spray) 8,486,972,
8,486,973,
8,835,459,
8,835,460,
9,241,935,
9,289,387,
9,642,797,
9,642,844
Biogen Int’l Gmbh v. Windlas Healthcare, Pvt. Ltd., 18-1361 (D. Del.) Aug. 31, 2018 Hon. Leonard P. Stark Tecfidera® (dimethyl fumarate delayed-release capsules) 6,509,376,
7,320,999
Celgene Corp. v. West-ward Pharms. Int’l Ltd., 18-13477 (D.N.J.) Aug. 31, 2018 Hon. Susan D. Wigenton Thalomid® (thalidomide capsules) 6,315,720,
6,561,977,
6,755,784,
6,869,399,
7,141,018,
7,230,012,
7,959,566,
8,315,886,
8,626,531
Sumitomo Dainippon Pharma Co., Ltd. v. Piramal Healthcare UK Ltd., 18-13478 (D.N.J.) Aug. 31, 2018 Hon. Stanley R. Chesler Latuda® (lurasidone HCl tablets) 9,815,827,
9,907,794
Symed Labs Ltd. v. Amneal Pharms. LLC, 18-13628 (D.N.J.) Sept. 6, 2018 Hon. Claire C. Cecchi linezolid tablets 7,351,824,
7,429,661
Valeant Pharms. North America LLC v. Zydus Pharms. (USA) Inc., 18-13635 (D.N.J.) Sept. 6, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Amgen Inc. v. Emcure Pharms. Ltd., 18-1393 (D. Del.) Sept. 7, 2018 Hon. Mitchell S. Goldberg Sensipar® (cinacalcet tablets) 9,375,405
Biodelivery Sciences Int’l, Inc. v. Alvogen Pb Research & Development LLC, 18-1395 (D. Del.) Sept. 7, 2018 Hon. Colm F. Connolly Belbuca® (buprenorphine buccal film) 8,147,866,
9,655,843,
9,901,539
Valeant Pharms. North America LLC v. Aurobindo Pharma USA Inc., 18-13693 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Solaris Pharma Corp., 18-13695 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Strides Pharma Inc., 18-13696 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Lupin Ltd., 18-13700 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Par Pharm., Inc., 18-13701 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Par Pharm., Inc., 18-8221 (S.D.N.Y.) Sept. 10, 2018 Hon. Edgardo Ramos Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01670 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,679,069
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01675 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,603,044
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01676 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,603,044
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01677 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,992,486
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01678 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,992,486
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01679 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,992,486
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01680 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 9,526,844
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01682 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 9,526,844
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01684 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 9,604,008
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01696 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 9,526,844
Sumitomo Dainippon Pharma Co., Ltd. v. Macleods Pharms. Ltd., 18-13833 (D.N.J.) Sept. 12, 2018 Hon. Stanley R. Chesler Latuda® (lurasidone HCl tablets) 9,815,827,
9,907,794
Alvogen Pine Brook LLC v. Celgene Corp., IPR2018-01714 (PTAB) Sept. 12, 2018 N/A Revlimid® (lenalidomide capsules) 7,968,569
Valeant Pharms. North America LLC v. Alkem Labs. Ltd., 18-13905 (D.N.J.) Sept. 14, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Alkem Labs. Ltd., 18-13954 (D.N.J.) Sept. 17, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Duke University v. Akorn, Inc., 18-14035 (D.N.J.) Sept. 19, 2018 Hon. Brian R. Martinotti Latisse® (bimatoprost ophthalmic solution) 9,579,270
Allergan, Inc. v. Amneal Pharms. LLC, 18-1457 (D. Del.) Sept. 20, 2018 Hon. Leonard P. Stark Restasis® (cyclosporine ophthalmic emulsion) 8,633,162,
8,642,556
Eagle Pharms., Inc. v. Slayback Pharma LLC, 18-1459 (D. Del.) Sept. 20, 2018 Hon. Colm F. Connolly Bendamustine HCl Injection) 8,609,707,
9,265,831,
9,572,796,
9,572,797,
10,010,533
Celgene Corp. v. Hetero Labs Ltd., 18-14111 (D.N.J.) Sept. 20, 2018 Hon. Esther Salas Pomalyst® (pomalidomide capsules) 9,993,467
Bayer Healthcare LLC v. Apotex Inc., 18-1465 (D. Del.) Sept. 21, 2018 Hon. Leonard P. Stark Stivarga® (regorafenib tablets) 9,957,232
Valeant Pharms. North America LLC v. Acrux DDS Pty Ltd., 18-14194 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Apotex Inc., 18-14202 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Macleods Pharms. Ltd., 18-14204 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Perrigo Pharma Int’l DAC, 18-14207 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Slayback Pharma, LLC, 18-14208 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Teva Pharms. USA, Inc., 18-14209 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Cipla Ltd., 18-14225 (D.N.J.) Sept. 24, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. KVK-Tech, Inc., Ltd., 18-14298 (D.N.J.) Sept. 26, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 18-14305 (D.N.J.) Sept. 26, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Adamis Pharms. Corp. v. Belcher Pharms., LLC, 18-2379 (M.D. Fla.) Sept. 26, 2018 Hon. William F. Jung Symjepi® (epinephrine for injection) 9,283,197,
10,004,700
Celgene Corp. v. Teva Pharms USA, Inc., 18-14366 (D.N.J.) Sept. 27, 2018 Hon. Esther Salas Pomalyst® (pomalidomide capsules) 9,993,467
Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 18-0184 (N.D.W.V.) Sept. 26, 2018 Hon. Irene M. Keeley Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. KVK-Tech, Inc., Ltd., 18-4195 (E.D. Pa.) Sept. 27, 2018 Hon. Paul S. Diamond Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Alembic Pharms. Ltd. v. GlaxoSmithKline LLC, 18-1513 (D. Del.) Sept. 28, 2018 Hon. Richard G. Andrews Lamictal® XR (lamotrigine extended-release tablets) 8,637,512,
9,144,547
Valeant Pharms. North America LLC v. Amneal Pharms. LLC, 18-14468 (D.N.J.) Sept. 28, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
GENERICally Speaking Fall 2018

Related Professionals

Oren D. Langer

Partner

Managing Partner, New York Office

Jeffrey Alan Hovden

Partner

Christopher A. Pinahs

Partner

RELATED SERVICES

Hatch-Waxman Litigation

Related Publications

First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
VIEW ALL

Related News

March 7, 2022
Robins Kaplan Attorneys Earn 2022 Readers' Choice Awards from JD Supra
October 26, 2021
Robins Kaplan Named “Recommended Firm” For Hatch-Waxman Litigation in 2021
August 2, 2021
Jake Holdreith Shortlisted by LMG Life Sciences for Hatch-Waxman Litigator of the Year
March 31, 2021
Robins Kaplan Attorneys Earn 2021 Readers' Choice Awards from JD Supra
October 12, 2020
Robins Kaplan Named “Recommended Firm” for Hatch-Waxman Litigation; Four Partners “life Sciences Stars”
VIEW ALL
Back to Top